This is a novel text that highlights the controversial areas in the management of gynecological cancers. None of the topics in this book have definitive answers; they represent the everyday decision-making facing gynecologists, oncologists, radiologists, pathologists and other health professionals treating women with these conditions. This book is not to be used as a traditional textbook; it is a text that specialists and trainees will use to help them weigh up the arguments that exist in a variety of areas in the treatment of gynecological cancers. Each chapter will have two or more authors, selected either for their opposing views or for their ability to provide an opposite view or opinion to the other. The content will be evidence-based, illustrating contrasting evidence and scientific opinion in the literature. Each chapter will close on a summary indicating the direction of research needed to address the issues being discussed.

A didactic scientific discussion of controversial issues International authorship including many key opinion leaders Text is concise, with a comprehensive literature review, clearly illustrating different and opposing sides to the controversies, concluding with a section on the direction of future research to resolve these issues

Klappentext
Gynecological cancers are some of the most commonly occurring malignancies in women. Despite their high incidence, treatment and management of these cancers remain controversial, with conflicting evidence about many aspects of the disease. Controversies in the Management of Gynecological Cancers offers a unique assessment of the opposing sides of the controversial issues associated with gynecological cancers, and aims to provide professionals in the field with a keener sense of the underlying evidence-base and a starting point from which to follow the ongoing debate. A section on the direction of future research to resolve these issues completes the discussion in each chapter. This book will appeal to specialists, trainees and healthcare workers in gynecological oncology, gynecologists, medical oncologists and radiation oncologists, and is an excellent starting point for anyone who wishes to gain a better understanding of the complex nature of the management of gynecological malignancy.

Inhalt

1. Controversies in the Treatment of Women with Early Stage Epithelial Ovarian Cancer.- 2. Recurrent Ovarian Cancer: When to Treat and How to Assess.- 3. New Views of Ovarian Carcinoma Types: How will this Change Practice?.- 4. Lymphadenectomy in Endometrial Cancer: The Controversy Rages Unabated.- 5. What is the Role of Adjuvant Radiotherapy and Chemotherapy in Endometrial Cancer?.- 6. Chemotherapy and/or Targeted Therapies for Advanced Endometrial Cancer: Time to Rethink?.- 7. Is Cervix Cancer a Disappearing Disease? Impact of HPV Vaccination in Developed Countries.- 8. What is the Role of Cytotoxic Chemotherapy in Advanced Cervical Cancer?.- 9. Response as a Measure of Treatment Efficacy in Clinical Trials: Should RECIST Be Abandoned?.- 10. What are the Treatment Options for Recurrent Ovarian Cancer?.- 11. How To Study Rare Gynaecological Tumours: Trials or Registries?.- 12. What is the Best Treatment Model for Gynaecological Cancers? Does Centralization Help?.- 13. When Should Surgery be Performed for the First-Line Treatment of Advanced Ovarian Cancer?.- 14. Does Intraperitoneal Therapy for Ovarian Cancer have a Future?.- 15. Maintenance Therapy for First-Line Treatment of Ovarian CancerIs this the Strategy for the Future?.- 16. What is the Value of Lymphadenectomy in Early Ovarian Cancer?.- 17. Sentinel Node BiopsyDoes it Help in the Management of Vulvar Cancer?.- 18. Controversies in the Management of Advanced Vulvar Cancer.- 19. Bowel Obstruction in Ovarian Cancer: To Operate or Not?.- 20. Early Cervical Cancer: Can Fertility be Safely Preserved?.- 21. What is the Role of PET/CT in Gynaecologic Cancers?.- 22. Do Intensity-Modulated Radiation, Image-Guided Radiation, and 3D Brachytherapy Significantly Advance Radiotherapeutic Management of Gynecologic Cancers?.- 23. What is the Place of Hormone Replacement Therapy in Ovarian, Endometrial, and Breast Cancer?.- 24. Familial Gynaecological Cancers: Whom to Screen and How to Manage?.- 25. TrialDesign: Should Randomized Phase III Trials in Gynaecological Cancers be Abandoned?.- 26. How Should Early Gestational Trophoblastic Disease be Managed?.- 27. Should Every Woman with Gynaecologic Cancer Undergo Routine Screening for Psychological Distress and Sexual Dysfunction?.- 28. How Should Gynaecological Sarcomas be Managed?.- 29. What is the Future of Immunotherapy in Ovarian Cancer?.